Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF

Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF

ObjectiveThis study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.Research design and methodsThis retrospective cohort stud...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhen-Yu Yang, Zhi-Yuan Zhang, Wei-Jie Zhang, Da Liu, Fu-Shi Piao, Xiangyu Yan, Fang-Tao Shi, Min Yang, Jing Chen, Sheng-song Zhu, Hong-Hou He, Pei-Hong Wu, Cheng Qian, Min Lin, Jun-Qing Feng, Chun-jin Lai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	HCM-HFpEF prognosis FT3 thyroid function all-cause mortality cardiac transplantation
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2025.1546309/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hepatocyte growth factor and B-type natriuretic peptide as independent predictors of mortality in HFpEF patients
by: Hou-liang Chen, et al.
Published: (2025-02-01)

Prognosis of early‐stage HFpEF in the community‐dwelling elderly: The Northern Shanghai Study
by: Weilun Meng, et al.
Published: (2025-02-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
by: Tomasz Urbanowicz, et al.
Published: (2024-11-01)

Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
by: Lingyun Luo, et al.
Published: (2025-04-01)

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF
by: Shenghua Zhou, et al.
Published: (2025-03-01)

Identification of noval diagnostic biomarker for HFpEF based on proteomics and machine learning
by: Muyashaer Abudurexiti, et al.
Published: (2025-04-01)

Sex‐related pathophysiological mechanisms may be present before symptoms of HFpEF develop
by: B. Wong, et al.
Published: (2025-06-01)

Schaftoside improves HFpEF through regulation the autophagy-lysosome pathway by allosterically targeting CaMKII-δ
by: Haiying Zhang, et al.
Published: (2024-12-01)

Sex differences in the association between nutritional status and in‐hospital mortality in HFpEF patients
by: Michał Czapla, et al.
Published: (2025-08-01)

Specific targeting of adipose tissue metabolism is superior to caloric restriction in treating obesity-related HFpEF
by: Simon Sedej, et al.
Published: (2025-07-01)

Cardiometabolic Phenotype in HFpEF: Insights from Murine Models
by: Ekaterina Ogurtsova, et al.
Published: (2025-03-01)

Gender-Specific Differences in Diastolic Dysfunction and HFpEF: Pathophysiology, Diagnosis, and Therapeutic Strategies
by: Francesca Coppi, et al.
Published: (2025-06-01)

The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
by: Xiangling Duan, et al.
Published: (2025-04-01)

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study
by: Arif Albulushi, et al.
Published: (2025-07-01)

Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis
by: Mingzhi Lin, et al.
Published: (2025-05-01)

Ventricular interdependent phenotype of mixed Cpc‐pulmonary hypertension and HFpEF with normal left atrium: Impact on CPET metrics and clinical outcomes
by: Giovanna Zampierollo‐Jaramillo, et al.
Published: (2024-10-01)

MyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction‐Regulating Proteins in a Rat Model of HFpEF
by: Beatrice Vahle, et al.
Published: (2025-06-01)

Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF
by: Katherine L. Dominic, et al.
Published: (2024-12-01)

Type 2 diabetes worsens the outcome of ischemia/reperfusion in female STEMI patients and female db/db mice with HFpEF cardiometabolic phenotype
by: Ivana Iveljic, et al.
Published: (2025-06-01)

Targeting atrial fibrillation in HFpEF: the emerging role of pulsed field ablation
by: A. S. Parwani, et al.
Published: (2025-07-01)

Microvascular dysfunction across organs in heart failure with preserved ejection fraction: the PROSE-HFpEF case-control study
by: Jerremy Weerts, et al.
Published: (2025-07-01)

Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF
by: Patrick A. Kwaah, MBChB, et al.
Published: (2025-07-01)

Atrial dysfunction: a contrast-free marker for HFpEF in obese diabetics—insights from comprehensive CMR and serum biomarker analyses
by: Rebecca Elisabeth Beyer, et al.
Published: (2025-06-01)

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
by: Satyam Sarma, et al.
Published: (2020-11-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Clinical profile of heart failure in geriatric patients in a tertiary cardiac hospital of Bangladesh
by: Mahbuba Yesmin, et al.
Published: (2025-06-01)

Single nuclei RNA-sequencing unveils alveolar macrophages as drivers of endothelial damage in obese HFpEF-related pulmonary hypertension
by: Era Gorica, et al.
Published: (2025-07-01)

Hospitalized patients and stimulant use-associated heart failure: importance of ejection fraction and related risk factors
by: Akshat Agrawal, et al.
Published: (2025-07-01)

Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
by: Kengo Ayabe, et al.
Published: (2024-10-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
by: Stephanie J. Rowe, BBiomed, MD, et al.
Published: (2025-01-01)

Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment
by: Era Gorica, et al.
Published: (2025-07-01)

Impact of Voluntary Exercise on Systemic Inflammation in a 2‐Hit Model of Heart Failure With Preserved Ejection Fraction
by: Heather Quiriarte, et al.
Published: (2025-02-01)

Cardiopulmonary exercise testing as a prognosis‐assessing tool in heart failure with preserved ejection fraction
by: C. Rozados daConceicao, et al.
Published: (2025-06-01)

Exploring the Noninvasive Evaluation of the Pulmonary Pressure–Flow Relationship During Exercise
by: Mads J. Andersen, et al.
Published: (2024-08-01)

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-05-01)

Correction: Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-07-01)

The Role of Inflammation in the Pathophysiology of Heart Failure
by: Marwan Amara, et al.
Published: (2025-07-01)

Intravenous iron in heart failure: still no prognostic impact, but questions remain
by: Ibrahim El-Battrawy, et al.
Published: (2025-08-01)

The use of sacubitril/valsartan in different forms of heart failure
by: Mohammad Abumayyaleh, et al.
Published: (2025-06-01)